Literature DB >> 3462442

A pharmacokinetic study of adriamycin and 4'epi-adriamycin after simultaneous intra-arterial liver administration.

S Eksborg, M Andersson, L Domellöf, U Lönroth.   

Abstract

The plasma pharmacokinetics of adriamycin and 4'epi-adriamycin were studied in patients with malignant tumors of the liver after simultaneous regional administration of equal amounts of the two anthracyclines by the arterial route. The use of a highly selective liquid chromatographic analytical method permitted quantification of plasma concentrations of the two drugs as well as their corresponding 13-hydroxy metabolites. The plasma concentrations of each drug followed a three-compartment open model. On average the area under the plasma concentration time curve (AUC) and the maximum plasma concentration (Cmax) were 2.1 and 1.7 times larger for adriamycin than for 4'epi-adriamycin, respectively. 4'Epi-adriamycin was eliminated faster than adriamycin, the terminal half-life time being on the average 1.5 times higher for adriamycin. These findings are in agreement with what has previously been observed after intravenous administration. The plasma concentrations of the 13-hydroxy metabolites did not exceed 30 ng ml-1. The AUC values of these metabolites were on average 20% of the AUC values of the intact drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3462442     DOI: 10.1007/BF02934562

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  23 in total

1.  A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.

Authors:  W D Ensminger; A Rosowsky; V Raso; D C Levin; M Glode; S Come; G Steele; E Frei
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  Liquid chromatography in anticancer drug research with special reference to anthraquinone glycosides.

Authors:  S Eksborg; H Ehrsson
Journal:  J Pharm Biomed Anal       Date:  1984       Impact factor: 3.935

3.  Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report.

Authors:  M M Bern; W McDermott; B Cady; R A Oberfield; C Trey; M E Clouse; J L Tullis; L M Parker
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

4.  Adriamycin metabolism in man. Evidence from urinary metabolites.

Authors:  S Takanashi; N R Bachur
Journal:  Drug Metab Dispos       Date:  1976 Jan-Feb       Impact factor: 3.922

5.  Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.

Authors:  C M Camaggi; E Strocchi; V Tamassia; A Martoni; M Giovannini; G Lafelice; N Canova; D Marraro; A Martini; F Pannuti
Journal:  Cancer Treat Rep       Date:  1982-10

6.  Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.

Authors:  S Eksborg; B J Cedermark; H S Strandler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

7.  Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration.

Authors:  Y T Lee; K K Chan; P A Harris; J L Cohen
Journal:  Cancer       Date:  1980-05-01       Impact factor: 6.860

8.  Pharmacokinetics of 4'-epi-doxorubicin in man.

Authors:  H Weenen; J Lankelma; P G Penders; J G McVie; W W ten Bokkel Huinink; M M de Planque; H M Pinedo
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

9.  Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.

Authors:  A Martini; E Moro; M A Pacciarini; V Tamassia; N Natale; E Piazza
Journal:  Int J Clin Pharmacol Res       Date:  1984

10.  Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.

Authors:  R T Chlebowski; K K Chan; M J Tong; J M Weiner; V M Ryden; J R Bateman
Journal:  Cancer       Date:  1981-09-01       Impact factor: 6.860

View more
  6 in total

Review 1.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 2.  Epirubicin. Clinical pharmacology and dose-effect relationship.

Authors:  J Robert
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of epirubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

4.  Effect of therapeutic concentrations of anthracyclines on monocyte phagocytosis of yeast cells.

Authors:  L Athlin; L Domellöf; B Norberg
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  A systems-based mathematical modelling framework for investigating the effect of drugs on solid tumours.

Authors:  Cong Liu; J Krishnan; Xiao Yun Xu
Journal:  Theor Biol Med Model       Date:  2011-12-07       Impact factor: 2.432

6.  Towards an integrated systems-based modelling framework for drug transport and its effect on tumour cells.

Authors:  Cong Liu; Xiao Yun Xu
Journal:  J Biol Eng       Date:  2014-01-13       Impact factor: 4.355

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.